AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of Fitostimoline soaked gauzes, Fitostimoline cream and Citrizan gel in the topical treatment of second-degree superficial cutaneous burns

Active, not recruiting

Conditions: Topical treatment of second-degree superficial cutaneous burns
MedDRA version: 6.1Level: PTClassification code 10006802

Registration Number: EUCTR2005-000897-38-IT

Lead Sponsor: FARMACEUTICI DAMOR

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Recruiting

Sex: All

Target Recruitment: 396

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):

Secondary Outcome Measures

Name	Time	Method

Related Trials

Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of heparan sulfate slow-release 120 mg tablets and defibrotide 400 mg capsules in the treatment of clinical findings of chronic venous insufficiency - ND

Active, Not Recruiting

FARMACEUTICI DAMOR

Updated 3/19/2012

Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)

RecruitingPhase 1

Catharina Ziekenhuis Stichting

Updated 7/22/2024

Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study

Active, Not RecruitingPhase 1

Catharina Hospital

Updated 4/15/2024

Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer

Active, Not RecruitingPhase 1

Catharina Ziekenhuis Eindhoven

Updated 5/21/2024

Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer - PelvEx II study

RecruitingPhase 3

Catharina-ziekenhuis

Updated 9/9/2024

Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study

Active, Not RecruitingPhase 1

Catharina Hospital

Updated 10/12/2021

Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients. - ND

Active, Not Recruiting

IBSA

Updated 3/19/2012

Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine (T4) soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients.

Active, Not RecruitingPhase 1

IBSA, Institut Biochimique SA

Updated 4/4/2022

Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.

Active, Not RecruitingPhase 1

Onxeo

Updated 4/30/2019

Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.

Active, Not RecruitingPhase 1

Onxeo

Updated 9/9/2024

Home Terms & Conditions Privacy Policy

AI-Powered Research

Premium Access

Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of Fitostimoline soaked gauzes, Fitostimoline cream and Citrizan gel in the topical treatment of second-degree superficial cutaneous burns

Recruitment & Eligibility

Study & Design

Related Research Topics

Related Trials

Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of heparan sulfate slow-release 120 mg tablets and defibrotide 400 mg capsules in the treatment of clinical findings of chronic venous insufficiency - ND

Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)

Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study

Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer

Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer - PelvEx II study

Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study

Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients. - ND

Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine (T4) soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients.

Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.

Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.

Clinical Trial Alerts